ARTICLE | Emerging Company Profile
Reverb: redirecting endogenous cytokines to tumors
Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue
March 20, 2024 11:48 PM UTC
Reverb is developing bispecific antibodies that target cytokines, but rather than blocking the cytokines, the biotech’s programs redirect them to cells of interest, such as tumor or immune cells.
Reverb Therapeutics Inc. was inspired by observations in the literature that antibodies targeting cytokines can increase cytokine activity by increasing their half-life. ...